Sco Capital Partners Llc Sells 73,411 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) Director Sco Capital Partners Llc sold 73,411 shares of the business’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $2.08, for a total value of $152,694.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Abeona Therapeutics stock opened at $2.01 on Wednesday. The firm’s 50-day moving average price is $2.51 and its 200 day moving average price is $2.66. Abeona Therapeutics Inc has a twelve month low of $1.35 and a twelve month high of $5.19.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.03. Sell-side analysts forecast that Abeona Therapeutics Inc will post -0.68 EPS for the current year.

Several brokerages have issued reports on ABEO. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Abeona Therapeutics in a research report on Monday, July 13th. Zacks Investment Research lowered Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 8th. Finally, ValuEngine upgraded Abeona Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, September 2nd. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $5.70.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABEO. BlackRock Inc. lifted its stake in Abeona Therapeutics by 47.4% in the 1st quarter. BlackRock Inc. now owns 3,665,382 shares of the biopharmaceutical company’s stock worth $7,697,000 after purchasing an additional 1,178,139 shares in the last quarter. American International Group Inc. increased its holdings in shares of Abeona Therapeutics by 54.2% during the 1st quarter. American International Group Inc. now owns 32,339 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 11,367 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Abeona Therapeutics by 35.7% during the 1st quarter. Rhumbline Advisers now owns 71,271 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 18,755 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Abeona Therapeutics by 24.6% during the 1st quarter. Bank of New York Mellon Corp now owns 248,982 shares of the biopharmaceutical company’s stock worth $524,000 after buying an additional 49,217 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Abeona Therapeutics by 55.4% during the 1st quarter. State Street Corp now owns 950,322 shares of the biopharmaceutical company’s stock worth $1,996,000 after buying an additional 338,756 shares during the last quarter. 51.22% of the stock is currently owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Further Reading: If I purchase shares through a brokerage account, am I the holder of record?

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.